Compare ORIS & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORIS | TVRD |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.2M | 37.3M |
| IPO Year | 2024 | N/A |
| Metric | ORIS | TVRD |
|---|---|---|
| Price | $1.49 | $4.68 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $51.67 |
| AVG Volume (30 Days) | ★ 631.8K | 141.3K |
| Earning Date | 04-30-2026 | 02-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $12,317,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $198.58 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.11 | $3.74 |
| 52 Week High | $45.60 | $43.65 |
| Indicator | ORIS | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 64.43 | 50.34 |
| Support Level | $1.34 | $4.39 |
| Resistance Level | $1.87 | $4.76 |
| Average True Range (ATR) | 0.20 | 0.33 |
| MACD | 0.01 | 0.12 |
| Stochastic Oscillator | 44.74 | 74.58 |
Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.